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Abstract
Background: Approximately 5–10% of breast cancers are hereditary and their biology and prognosis appear to
differ from those of sporadic breast cancers. In this study we compared the biological features and clinical
characteristics of non metastatic breast cancer in patients with BRCA mutations versus patients with a family history
suggesting hereditary breast cancer but without BRCA mutations (BRCA wild type) versus patients with sporadic
disease, and correlated these findings with clinical outcome.
Methods: We retrieved the clinical and biological data of 33 BRCA-positive, 66 BRCA-wild type and 1826 sporadic
breast cancer patients contained in a single institution clinical database between 1980 and 2012. Specifically, we
recorded age, tumor size, nodal status, treatment type, pattern of relapse, second primary incidence, outcome
(disease-free survival and overall survival), and biological features (estrogen receptor [ER], progesterone receptor
[PgR], tumor grade, proliferation and c-erbB2 status). Median follow-up was 70 months.
Results: BRCA-positive patients were significantly younger than sporadic breast cancer patients, and less likely to be
ER-, PgR- or c-erbB2-positive than women with BRCA-wild type or sporadic breast cancer. Tumor size and grade,
nodal status and proliferation did not differ among the three groups. Rates of radical mastectomy were 58, 42 and
37%, and those of conservative surgery were 42, 58 and 63% in women with BRCA-positive, BRCA-wild type and
sporadic breast cancer (p = 0.03), respectively. The incidence of contralateral breast cancer was 12, 14 and 0%
(p <0.0001) and the incidence of second primary tumors (non breast) was 9, 1 and 2% (p <0.0001) in BRCA-positive,
BRCA-wild type and sporadic breast cancer, respectively. Median disease-free survival in years was 29 in BRCA-wild
type, 19 in BRCA-positive and 14 in sporadic breast cancer patients (log-rank = 0.007). Median overall survival in
years was not reached for BRCA-wild type, 19 for BRCA-positive and 13 for sporadic breast cancer patients
(log-rank <0.0001). At multivariate analyses only BRCA-wild type status was related to a significant improvement
in overall survival versus the sporadic breast cancer group (HR = 0,51; 95% CI (0,28–0,93) p = 0.028).
Conclusions: The biology and outcome of breast cancer differ between patients with BRCA mutations, patients
with a family history but no BRCA mutations and patients with sporadic breast cancer.
Background
Carcinoma of the breast is a biologically heterogeneous
disease. Approximately 5–10% of all breast cancers have
a hereditary background. BRCA1 and BRCA2 mutations
account for 25–28% of hereditary breast cancers [1].
Young women are more likely to have BRCA-associated
breast cancer than to be affected by sporadic disease,
and BRCA-positive cancers are usually high grade and
lack hormone receptors [2]. Compared with sporadic
cancer, the prognosis of BRCA-positive cancer has been
reported to be worse [3, 4] not different [5, 6] or better
[7]. In about 70% of families with aggregation of breast
and ovarian cancers and a pedigree strongly suggesting
hereditary breast cancer, the BRCA test was negative
and no pathogenic mutation was identified [8–12]. This
subgroup of familial non-BRCA mutated breast cancers are
very heterogeneous and not well defined in terms of
histopathological features, clinical presentation and
prognosis. Moreover, little is known about the biological
features of BRCA-mutated and of BRCA-wild type breast
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cancer in relation to their clinical outcome. Therefore, we
compared the features of BRCA-mutated, BRCA-wild type
and sporadic breast cancer recorded in a large database in
the attempt to shed light on their biological phenotype and
clinical behavior, and to obtain information that might aid
clinical decision making and studies exploring the bio-
logical nature of this disease.
Methods
Patients’ characteristics
From 1980 to 2012, patients with breast cancer presenting
at our Department were screened for family history of
cancer and referred to the genetic counseling service, if
eligible. To be eligible for cancer genetic counseling,
patients had to fulfill one of two criteria: 1) a personal
history suggesting a genetic risk (i.e., early onset breast
cancer, breast and ovarian cancer in the same subject, and
multiple cancers besides breast and ovarian cancers in the
same subject); and 2) a significant family history of breast
and/or ovarian cancer defined as: (a) at least 2 cases of
breast cancer in family members below the age of 50 years
or ovarian, peritoneal or tubal cancer in family members
at any age; (b) 3 cases of breast cancer or ovarian, periton-
eal or tubal cancer in family members at any age; or (c) 1
case of breast cancer in a family member below the age of
50 years or bilateral breast cancer in a family member at
any age. Cancer genetic counseling was conducted accord-
ing to the model previously described [13].
Risk assessment was performed with two predictive
models: the clinical criteria of Modena [14] and BRCApro
[15, 16]. Patients considered at high risk for a BRCA muta-
tion according to the clinical criteria of Modena and/or a
BRCApro test (total score ≥10%) underwent genetic testing
for BRCA1 and BRCA2 mutations [17, 18]. Mutation
analysis was carried out at the Genetic Oncology Section,
Division of Surgical, Molecular and Ultrastructural Path-
ology, University of Pisa. Genomic DNA was extracted from
peripheral blood lymphocytes according to a standard
protocol. Mutational screening of BRCA1 and BRCA2 was
carried out by direct sequencing. DNA sequencing was
carried out directly on PCR-purified products using the
BigDye terminator v 3.1 sequencing kit (Applied Biosystems,
Foster City, CA) and different primers (primer sequences
available upon request). Capillary gel electrophoresis and
data collection were carried out with an automated DNA
sequencer (ABI PRISM 3100, Applera, Norwalk, CT).
Sequence analyses were conducted with the Seq-Scape
Software (Applied Biosystems). Mutation nomenclature for
the BRCA1 and BRCA2 genes is as used in the BIC database
according to the recommendations of GenBank [19].
Data were collected from 1946 women with stage I, IIA,
IIB, IIIA or IIIB breast cancer at our Department between
1980 and 2012. Biological and clinical information for this
analysis were extracted from a clinical database containing
the patients’ charts. No patient enrolled in this study had
received bilateral prophylactic mastectomy or prophylactic
oophorectomy. A total of 120 patients were eligible for
genetic testing for BRCA1 and BRCA2 mutations, according
to the criteria described above. The remaining 1826 patients
were considered to have a sporadic breast cancer as no clear
hereditary pattern was identified. These patients did not
undergo genetic testing for BRCA1 and BRCA2 mutations.
Among the 120 patients with a known BRCA status, 33
women were positive for a BRCA1 and/or BRCA2
mutation (BRCA-positive), 66 women were negative for a
BRCA1 and/or a BRCA2 mutation (BRCA-wild type) and
were considered to have familial non-BRCA mutated breast
cancer, and 21 patients had genetic alterations classified
“variants of unknown significance”. These patients were
excluded from the present study because of the uncertain
biologic or clinical relevance of these variants.
The clinical and pathological features of patients with
BRCA-positive breast cancer were assessed and compared
to those of patients with BRCA-wild type or sporadic breast
cancer. Type of treatment, rates of relapse (local and
distant), second primary and contralateral breast cancer
onset, disease-free survival and overall survival were also
compared among the three groups. Institutional Review
Board approval was waived as all patients signed informed
consent to anonymous data treatment for scientific purpose
according to Italian law (art.13, D.lgs. 196/2003).
Statistical analysis
The patients’ characteristics were compared using the χ2
test and an asymptotic Fisher’s exact test for categorical
variables and t tests for continuous variables. Disease-
free survival was calculated as the time from diagnosis
to first recurrence (local or distant); cause-specific
survival was calculated as the time from diagnosis to
death for that cancer, or to censoring if the patient was
alive at the last follow-up. Rates of recurrence and
second primaries of the three groups (BRCA-positive,
BRCA-wild type, sporadic breast cancer) were calculated
by dividing the number of events by the total person-
time at risk. Unadjusted relative risks (rate ratios) were
obtained by dividing the event rate in the screened
group by the event rate in the symptomatic groups [20].
The univariate effect of key tumor characteristics on risk
of recurrence and death was examined within each
patient group. Overall and disease-free survival curves
were constructed with Kaplan-Meier analyses and
compared using the two-sided log-rank test. The SPSS
statistical package version 20.0 (SPSS Inc, Chicago, IL)
was used for statistical analysis. A p-value <0.05 was
considered statistically significant. All patients enrolled
in this study had been treated and followed up at our
Department.
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Results
Clinical and pathological characteristics
The data of 1946 patients with non metastatic breast cancer
were recorded in the database of the Breast Oncology
Division of the University of Naples Federico II between
1980 and 2012. Of these, 1826 patients had sporadic breast
cancer, 33 had BRCA-positive cancer (19 BRCA1-mutated
and 14 BRCA2-mutated) and 66 had BRCA-wild type
breast cancer. As shown in Table 1, BRCA-positive patients
were significantly younger than sporadic breast cancer
patients, and were less likely to be positive for estrogen
receptor (ER), progesterone receptor (PgR) or human
epidermal growth factor receptor (c-erbB2) than women
with BRCA-wild type or sporadic breast cancer. In detail, in
patients with BRCA-positive, BRCA-wild type and sporadic
cancer, respectively, 54, 67 and 80% (p < 0.0001) of tumors
were ER-positive, 54, 68 and 74% (p = 0.04) were PgR-
positive, and 9, 36 and 17% (p = 0.01) were c-erbB2-
positive. No statistically significant difference in tumor size,
nodal status, grading or proliferation, measured as Ki67,
was observed among the three study groups. The type of
local and systemic treatment of the primary tumor dif-
fered significantly among the three groups (Table 2).
Radical mastectomy was more frequent among BRCA-
positive and BRCA-wild type patients (58% vs. 42% vs.
37% in BRCA-positive vs. BRCA-wild type vs. sporadic
breast cancer, p < 0.03). As expected from the distribution
of ER, the rate of only chemotherapy as systemic
Table 1 Patient Demographics and Clinical Characteristics
BRCA-positive BRCA-wild type Sporadic p-value
Number of patientsa 33 66 1826
N % N % N %
Age at diagnosis <0.0001
≤ 35 14 43 11 16 102 6
36–45 10 30 33 50 421 23
46–55 5 15 11 17 547 30
≥ 56 4 12 11 17 756 41
Tumor size N = 24 N = 56 N = 1560 0.79
< =2 cm 10 42 31 55 790 51
> 2 cm, <=5 cm 12 50 20 36 652 42
> 5 2 8 5 9 118 7
Nodal status N = 28 N = 59 N = 1593 0.46
Node negative 13 46 34 58 793 50
Node positive 15 54 25 42 800 50
Tumor grade N = 20 N = 48 N = 1435 0.07
1 1 5 6 13 82 6
2 4 20 14 29 574 40
3 15 75 28 58 779 54
ER status N = 26 N = 55 N = 1545 <0.0001
Positive 14 54 37 67 1238 80
Negative 12 46 18 33 307 20
PgR status N = 26 N = 54 N = 1531 0.04
Positive 14 54 37 68 1136 74
Negative 12 46 17 32 395 26
Ki67 status N = 21 N = 29 N = 1079 0.87
Low 6 29 10 35 327 30
High 15 71 19 65 752 70
cerb-B2 status N = 22 N = 33 N = 1069 0.01
Negative 20 91 21 64 884 83
Positive 2 9 12 36 185 17
ER estrogen receptor, PgR progesterone receptor
aThe 21 patients carrying variants of unknown significance were excluded from the analysis. Comparisons were made by Chi-square test/asymptomatic Fisher’s exact test
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treatment was higher in BRCA-positive patients than in
either BRCA-wild type or sporadic breast cancer patients
(41% vs. 27% vs. 22%). Rates of adjuvant hormone therapy
without chemotherapy were lower in the BRCA-positive
patients (13% vs. 23% vs. 24% in BRCA-positive vs.
BRCA-wild type vs. sporadic breast cancer patients), and
fewer BRCA-wild type patients received chemotherapy
followed by endocrine therapy (37% vs. 26% vs. 49% in
BRCA-positive vs. BRCA-wild type vs. sporadic breast
cancer patients) compared to the other two study groups.
All the differences in the type of adjuvant systemic treat-
ment delivered in the three study groups were statistically
significant (p < 0.0001).
Clinical outcomes
The median follow-up time was 70 months (range: 13–421
months). The development of recurrence differed signifi-
cantly among the three groups (27% vs. 33% vs. 29% in
BRCA-positive vs. BRCA-wild type vs. sporadic breast can-
cer, respectively). In detail, BRCA-positive-breast cancer pa-
tients and BRCA-wild type breast cancer patients were more
prone to develop contralateral breast cancer (12% vs. 14% vs.
0% in BRCA-positive vs. BRCA-wild type vs. sporadic breast
cancer, respectively) and BRCA-positive breast cancer
patients were more prone to develop second non-breast
primary tumors (9% vs. 1% vs. 2% in BRCA-positive vs.
BRCA-wild type vs. sporadicbreast cancer, respectively). All
these data were statistically significant (p < 0.0001) (Table 3).
Table 4 shows the recurrence rate and breast cancer
mortality in relation to BRCA status. The recurrence rate
was 35 per 1000 person-years (95% CI 16–66), 31 per 1000
person-years (95% CI 20–47) and 48 per 1000 person-years
(95% CI 45–53), and the rates of overall survival were 32
per 1000 person-years (95% CI 15–59), 22 per 1000 person-
years (95% CI 13–35) and 40 per 1000 person-years (95% CI
37–43) in BRCA-positive vs BRCA-wild type vs sporadic
breast cancer. As shown in Fig. 1, disease-free survival
differed significantly among the three groups (log-rank =
0.007). The median disease-free survival in years was 29
(16–42) for BRCA-wild type, 19 (10–28) for BRCA-positive
and 14 (13–15) for sporadic breast cancer patients. Overall
survival differed significantly among the three groups (log-
rank <0.0001). Median overall survival in years was not
reached for BRCA-wild type, 19 (12–26) for BRCA-positive
and 13 (12–14) for sporadic breast cancer patients (Fig. 2).
However, at multivariate analyses including all three study
groups and adjusted for age, year of diagnosis, tumor stage
at diagnosis and ER and PgR status, only BRCA-wild type
status was related to a statistically significant improvement
in overall compared to the sporadic breast cancer group
(HR= 0,51; 95% CI 0,28-0,93; p=0.028).
Discussion
Here we provide evidence that the presentation and out-
come of breast cancer differ between patients with a
strong family history, with or without a BRCA mutation,
and patients with sporadic breast cancer. Consistent with
previous reports [21–23], most of our BRCA-mutated
patients were below the age of 35 years, whereas most
patients with sporadic cancer were above the age of
Table 2 Type of treatments according to BRCA status
BRCA-positive BRCA-wild type Sporadic p-value
N % N % N %
Type of surgery N = 33 N = 64 N = 1825 0.03
Mastectomy 19 58 27 42 670 37
Conservative 14 42 37 58 1155 63
Adjuvant therapy N = 32 N = 66 N = 1826 <0.0001
No therapy 3 9 16 24 88 5
Only CT 13 41 18 27 400 22
Only HT 4 13 15 23 437 24
CT + HT 12 37 17 26 901 49
The 21 patients carrying variants of unknown significance were excluded from
the analysis
CT chemotherapy, HT hormone therapy
Table 3 Recurrence, contralateral breast cancer and second
primary rates according to BRCA status
BRCA-positive BRCA-wild type Sporadic p-value
N % N % N %
N = 33 N = 66 N = 1826 <0.0001
No events 17 52 34 51 1264 69
Recurrence 9 27 22 33 522 29
Contralateral Breast 4 12 9 14 6 0
Second primarya 3 9 1 1 34 2
The 21 patients carrying variants of unknown significance were excluded from
the analysis
aSecond primaries are defined as all non breast second primaries









BRCA-positive 257 9 35 (16–66)
BRCA-wild
type
702 22 31 (20–47)
Sporadic 12721 522 48 (45–53)
OS
BRCA-positive 312 10 32 (15–59)
BRCA-wild
type
814 18 22 (13–35)
Sporadic 14943 598 40 (37–43)
The 21 patients carrying variants of unknown significance were excluded from
the analysis
CI confidence interval, DFS disease-free survival, OS overall survival
aRates were calculated from the reference date (i.e. date of diagnosis)
bConfidence interval by Haenszel et al. JNCI 1962
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46 years. The incidence of BRCA-wild type breast cancer
was higher among women between the ages of 36 and
55 years. In terms of tumor characteristics, we found no
difference in tumor size or nodal status at diagnosis
among the three study groups. However, tumor biology
differed depending on BRCA mutation status. BRCA-
positive breast cancers were more likely to be ER-negative
and/or PgR-negative and less likely to display c-erbB2
overexpression than either BRCA-wild type or sporadic
tumors. Interestingly, there was also a trend, albeit not
significant, for BRCA-positive tumors to be grade 3 and to
have a higher proliferation rate than the other two types
of tumors. These data are consistent with previous studies
showing that only a minority of BRCA1-mutated breast
cancers have high ER expression rates or overexpress c-
erbB2 [24], and that most BRCA-mutated tumors are
high-grade and have a higher proliferation fraction com-
pared with sporadic tumors [25, 26].
BRCA-wild type breast cancers have often been reported
to be low grade and have biologic features similar to those
of sporadic cancers [27, 28]. However, the data are not
consistent. In the present study, we found higher c-erbB2
Fig. 1 Disease-free survival. Disease-free survival in patients with BRCA-positive, BRCA-wild type or sporadic breast cancer
Fig. 2 Overall survival. Overall survival in patients with BRCA-positive, BRCA- wild type or sporadic breast cancer
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overexpression and a trend towards a higher incidence of
grade 1 cancers among BRCA-wild type patients compared
to the other two groups.
In our study, patients with BRCA-positive and BRCA-
wild type breast cancer were managed, in general, some-
what differently from patients with sporadic disease. In
fact, BRCA-positive patients and, albeit to a lesser extent,
BRCA-wild type patients underwent mastectomy more
frequently than women with sporadic breast cancer.
Although this tendency for mastectomy may be related to
the bias of the patient and/or the surgeon rather than to
BRCA mutation status, which was unknown at diagnosis,
the choice of these procedures is also influenced by the
patient’s age and tumor phenotypic characteristics.
Regarding systemic therapy, because BRCA-positive and
BRCA-wild type breast cancer are more frequently steroid
receptor-negative tumors, more BRCA-positive and BRCA
wild type patients received adjuvant chemotherapy ther-
apy than did sporadic breast cancer patients.
Despite the importance of family history as a risk
factor for breast cancer [29], there is disagreement about
its impact on prognosis of breast cancer patients with a
strong family history associated or not to a BRCA muta-
tion [30–33]. In our study, disease-free and overall
survival did not differ significantly between women with
BRCA-positive breast cancer and women with sporadic
breast cancer. This is in line with reports that survival is
not worse in patients with hereditary breast cancer,
particularly if adjuvant chemotherapy is administered
[34–39]. BRCA mutations render cancer cells more sen-
sitive to DNA breaking agents such as alkylating agents
and platinum salts, which are often used in adjuvant
treatment. Most of our BRCA-mutation carriers received
adjuvant chemotherapy. The increased susceptibility to
and the very high rate of adjuvant chemotherapy among
BRCA-mutation carriers in our series may have contrib-
uted to their not worse prognosis compared to patients
with sporadic breast cancer. Interestingly, at multivariate
analyses, overall survival was better in BRCA-wild type
breast cancer patients than in patients with sporadic
breast cancer. Further studies are needed to clarify the
genetic background of these tumors and, eventually, to
determine whether their increased genetic instability re-
sults in a better outcome of anticancer therapies.
In line with previous studies showing that BRCA-
mutated breast cancer patients have a strong lifetime risk
of developing a second primary cancer [40–43], we found
that the incidence of second primary cancers was signifi-
cantly higher in BRCA-positive patients than in the other
two groups. Not surprisingly, we also found that the most
frequent second primary in BRCA carrier patients was
breast cancer in the contralateral breast. Estimates of
contralateral breast cancer incidence among BRCA mu-
tated breast cancer patients varies from 15 to 40% within
10 years [39, 44–48]. None of our BRCA-positive patients
underwent prophylactic bilateral mastectomy and rate of
contralateral breast cancer in this subgroup was about 12%.
Little is known about the contralateral breast cancer risk
in women with BRCA-wild type breast cancer. However,
despite the lack of its efficacy, prophylactic bilateral mast-
ectomy after a first breast cancer is being increasingly re-
quested not only by mutation carriers but also by patients
with familial non-BRCA mutated breast cancer, especially
if the family history strongly suggests hereditary disease
[49–52]. In our series, the incidence of a second primary
among BRCA-wild type patients was about 15%. Most sec-
ond primaries were contralateral breast cancer (14%). This
rate is higher than reported previously [42, 53]. Several
studies have shown that contralateral breast cancer risk in
familial non-BRCA-mutated breast cancer patients varies
depending on the patient’s age at the first breast cancer
diagnosis [42, 48, 54]. In fact, women older than 50 years
when diagnosed with breast cancer had a significantly
lower risk of contralateral breast cancer (cumulative inci-
dence of contralateral breast cancer 12.9%) than women
diagnosed before the age of 40 years (cumulative incidence
of contralateral breast cancer 28.4%) [42, 48, 54]. In our
BRCA-wild type patients, the young age at diagnosis (most
patients were below the age of 45 years) and the absence of
prophylactic bilateral mastectomy may have accounted for
the increased incidence of contralateral breast cancer we
found in this subgroup.
Our study has several strengths. It is a single institution
study of the prognostic effects of BRCA mutations and a
family history suggestive of hereditary disease on breast
cancer outcome in women monitored for almost 15 years.
All patients with a family history suggestive of hereditary
disease underwent genetic counseling and risk assessment.
Genetic testing was conducted only if the patient was con-
sidered at high risk for a BRCA mutation according to the
clinical criteria of Modena [14] and BRCA pro [15, 16].
The limits of our study are the retrospective nature of the
analyses and the relatively low numbers of BRCA1 and
BRCA2 mutation carriers identified. Indeed, the stringent
criteria used to decide whether to conduct genetic testing
(genetic testing was carried out only if patients were consid-
ered at high risk for a BRCA mutation) and the prevalence of
Caucasian not Ashkenazi patients may account for the rela-
tively low incidence of BRCA mutation found in our dataset.
Importantly, the low number of events that occurred in these
carriers may have affected the precision of our analyses. Fi-
nally, we did not examine the effects of breast surgery (lump-
ectomy versus mastectomy) or of different types of adjuvant
chemotherapies on locoregional events or other outcomes.
Conclusions
Breast cancers in BRCA-mutation carriers and BRCA-wild
type patients differ from those in women with sporadic
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breast cancers in terms of age at presentation, hormone re-
ceptor and c-erbB2 status, type of local and systemic adju-
vant therapy received and second primary incidence. These
clinical and biological differences translated into outcome
differences with a better overall survival in the BRCA-wild
type patients than in patients with sporadic breast cancer.
Notably, there was a high incidence of contralateral breast
cancer in patients with BRCA-wild type breast cancer.
Should these results be confirmed by other studies, prophy-
lactic bilateral mastectomy may become a reasonable op-
tion in this subset of patients.
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